Skip to content

Blastocystis and Cryptosporidium Infection in Colorectal Cancer Patients

Blastocystis and Cryptosporidium Infection in Colorectal Cancer Patients

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06379035
Enrollment
54
Registered
2024-04-23
Start date
2024-11-01
Completion date
2025-12-31
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blastocystis Infection, Colorectal Cancer, Cryptosporidium Infection

Brief summary

1. Detect the prevelance of Blastocystis spp. and Cryptosporidium spp. among patients with colorectal cancer attending South Egypt Cancer Institute-Assiut University. 2. Detect the effect of Blastocystis and Cryptosporidium infection on various cytokines level in CRC patients that may be involved in the tumor progression.

Interventions

DIAGNOSTIC_TESTELISA / PCR

Multiplex PCR for confirmation of diagnosis of Blastocystis and Cryptosporidium infection. Enzyme linked immunosorbent assay (Elisa) for detection of : Different cytokines level in Colorectal cancer patients that may be involved in the tumor progression due to Blastocystis and Cryptosporidium infection.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* The persons selected for the study are those who are: 1. Colorectal cancer confirmed patients by imaging techniques (CT or MRI) and histopathological biopsy by Colonoscopy. 2. Cooperative individuals attending South Egypt Cancer Institute - Assiut University of all ages and both sexes with confirmed diagnosis of CRC who agreed to be engaged in the study and were able to provide adequate samples. CRC Patients will be divided into 4 groups: Group 1: CRC patients without Blastocystis or Cryptosporidium infection. Group 2 : CRC patients with Blastocystis infection. Group 3 : CRC patients with Cryptosporidium infection. Group 4 : CRC patients with both Blastocystis and Cryptosporidium infection.

Exclusion criteria

* Patients having any type of tumors other than CRC. Patients taking anti-parasitic medications 2 weeks before sample collection.

Design outcomes

Primary

MeasureTime frame
Detect the prevelance of Blastocystis spp. and Cryptosporidium spp. among patients with colorectal cancer attending South Egypt Cancer Institute-Assiut University.Baseline

Secondary

MeasureTime frame
Detect the effect of Blastocystis and Cryptosporidium infection on various cytokines level in CRC patients that may be involved in the tumor progression.Baseline

Contacts

Primary ContactMerna Hany, Master
mirnahany14497@aun.edu.eg01227994945

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026